Terms: = Pancreatic cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70 AND Treatment
8108 results:
1. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
Pei F; Tao Z; Lu Q; Fang T; Peng S
World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs.
Wei M; Lu L; Luo Z; Ma J; Wang J
BMC Gastroenterol; 2024 Apr; 24(1):142. PubMed ID: 38654165
[TBL] [Abstract] [Full Text] [Related]
3. [A Case of Advanced Gastric cancer Treated with Conversion Surgery followed by Nivolumab Combination Chemotherapy].
Sekino N; Natsume T; Tanaka H; Kainuma O; Sato Y; Note H; Yoshioka T; Kamata T; Odera H; Uchiyama M; Maruyama T; Takahashi H; Hirano S
Gan To Kagaku Ryoho; 2024 Apr; 51(4):417-420. PubMed ID: 38644309
[TBL] [Abstract] [Full Text] [Related]
4. [The efficacy and safety of laparoscopic radical gastrectomy after neoadjuvant chemotherapy combined with immunotherapy and targeted therapy].
Shao XX; Li WK; Hu HT; Lu YM; Jiang YJ; Tian YT
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1397-1402. PubMed ID: 38644290
[No Abstract] [Full Text] [Related]
5. [cancer survival analysis in Tianjin, 2010 to 2016].
Wang C; Shen CF; Xun LN; Zhang S; Zhang H; Zheng WL; Wang DZ
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):319-325. PubMed ID: 38644267
[No Abstract] [Full Text] [Related]
6. Prognostic value of combined psoas muscle mass and controlling nutritional status in patients with pancreatic ductal adenocarcinoma: a retrospective cohort study.
Kuwabara S; Takeuchi Y; Sato O; Mizota T; Ichinokawa M; Murakawa K; Aoki Y; Ishido K; Ono K; Hirano S
BMC Surg; 2024 Apr; 24(1):116. PubMed ID: 38643112
[TBL] [Abstract] [Full Text] [Related]
7. Defining distal splenopancreatectomy by the mesopancreas.
Safi SA; Alexander A; Neuhuber W; Haeberle L; Rehders A; Luedde T; Esposito I; Fluegen G; Knoefel WT
Langenbecks Arch Surg; 2024 Apr; 409(1):127. PubMed ID: 38625602
[TBL] [Abstract] [Full Text] [Related]
8. treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer.
Zhang LT; Zhang Y; Cao BY; Wu CC; Wang J
World J Gastroenterol; 2024 Mar; 30(12):1739-1750. PubMed ID: 38617739
[TBL] [Abstract] [Full Text] [Related]
9. Effects of neoadjuvant chemotherapy
Csontos A; Fazekas A; Szakó L; Farkas N; Papp C; Ferenczi S; Bellyei S; Hegyi P; Papp A
World J Gastroenterol; 2024 Mar; 30(11):1621-1635. PubMed ID: 38617451
[TBL] [Abstract] [Full Text] [Related]
10. Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in pancreatic Ductal Carcinoma.
Fujiwara-Tani R; Sasaki T; Bhawal UK; Mori S; Ogata R; Sasaki R; Ikemoto A; Kishi S; Fujii K; Ohmori H; Sho M; Kuniyasu H
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612866
[TBL] [Abstract] [Full Text] [Related]
11. Feasibility, safety and oncological short-term outcome of laparoscopic pancreaticoduodenectomy for periampullary cancer: Findings from a large sample from Vietnam.
Pham HM; Le Quan AT; Nguyen BH
Medicine (Baltimore); 2024 Apr; 103(15):e37769. PubMed ID: 38608081
[TBL] [Abstract] [Full Text] [Related]
12. Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.
Zeng D; Yu C; Chen S; Zou L; Chen J; Xu L
World J Surg Oncol; 2024 Apr; 22(1):93. PubMed ID: 38605359
[TBL] [Abstract] [Full Text] [Related]
13. Modified technique of Hepatojejunostomy for biliary tract reconstruction after resection of tumors affecting the perihilar region: a case series.
Kuang Y; Ji R; Yuan T; Liu M
BMC Surg; 2024 Apr; 24(1):102. PubMed ID: 38600548
[TBL] [Abstract] [Full Text] [Related]
14. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H; Tsuda T; Sunakawa Y; Shimokawa M; Akiyoshi K; Tokunaga S; Shoji H; Kunieda K; Kotaka M; Matsumoto T; Nagata Y; Mizukami T; Mizuki F; Danenberg KD; Boku N; Nakajima TE
Cancer Med; 2024 Apr; 13(7):e7107. PubMed ID: 38591098
[TBL] [Abstract] [Full Text] [Related]
15. Short- and long-term outcomes after distal pancreatectomy with radiologic infiltration of splenic vessels for pancreatic ductal adenocarcinoma.
Blanco-Fernández G; Serradilla-Martín M; Rotellar F; Latorre R; Jaén-Torrejimeno I; Muñoz-Forner E; Villodre C; Carabias-Hernández A; Kälviäinen-Mejía HK; Gordillo SE; de la Plaza R; Armas-Conde N; Garcés-Albir M; Morote SC; Manuel-Vázquez A; Serrablo A; Pardo F; Sabater L; Muñoz MPS; Ramia JM
J Gastrointest Surg; 2024 Apr; 28(4):467-473. PubMed ID: 38583897
[TBL] [Abstract] [Full Text] [Related]
16. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
17. A Network Meta-analysis of the Efficacy of Drug Therapy in First-line treatment of Advanced Hepatocellular Carcinoma.
Wang X; Peng G; Li J
J Gastrointestin Liver Dis; 2024 Mar; 33(1):94-101. PubMed ID: 38554414
[TBL] [Abstract] [Full Text] [Related]
18. Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and 'salvage' in patients with high risk locally advanced rectal cancers - tolerance and early outcomes.
Prajapati R; Ostwal V; Srinivas S; Engineer R; Bhargava P; Saklani A; D'Souza A; Kumar S; Peelay Z; Manali P; Ramaswamy A
J Cancer Res Ther; 2024 Jan; 20(1):199-203. PubMed ID: 38554321
[TBL] [Abstract] [Full Text] [Related]
19. A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.
Shi JM; Li N; Jiang LM; Yang L; Wang SL; Song YW; Liu YP; Fang H; Lu NN; Qi SN; Chen B; Li YX; Zhao DB; Tang Y; Jin J
Sci Rep; 2024 Mar; 14(1):7522. PubMed ID: 38553594
[TBL] [Abstract] [Full Text] [Related]
20. Circulating tumor-associated antigen-specific IFNγ
Murakami H; Takahama S; Akita H; Kobayashi S; Masuta Y; Nagatsuka Y; Higashiguchi M; Tomokuni A; Yoshida K; Takahashi H; Doki Y; Eguchi H; Matsuura N; Yamamoto T
Front Immunol; 2024; 15():1363568. PubMed ID: 38550601
[TBL] [Abstract] [Full Text] [Related]
[Next]